Similarly, patients with obesity who were taking a reduced dose of the CYP3A4 substrate drug concomitantly with posaconazole should also observe the same washout period before resuming the recommended monotherapy maintenance dose. The gene discussed is CYP3A4; the disease is obesity due to melanocortin 4 receptor deficiency.